| Literature DB >> 35144634 |
Chihiro Inoue1,2, Sachiko Konosu-Fukaya3, Kazuhiro Murakami3, Ryoko Saito-Koyama4,5, Hirofumi Watanabe5, Hideki Mitomo6, Naoya Ishibashi6, Takafumi Sugawara6, Toshiharu Tabata6, Hironobu Sasano4,5, Yasuhiro Nakamura3.
Abstract
BACKGROUND: Pulmonary carcinoid tumors rarely coexist with non-small cell lung carcinoma, and only nine cases have been reported previously. The pathogenesis and origin of these combined tumors remain unclear because of its rarity. CASEEntities:
Keywords: Adenocarcinoma; Carcinoid tumor; Case report; Collision tumor; Composite tumor; Lung cancer
Mesh:
Year: 2022 PMID: 35144634 PMCID: PMC8832797 DOI: 10.1186/s13000-022-01208-5
Source DB: PubMed Journal: Diagn Pathol ISSN: 1746-1596 Impact factor: 2.644
Fig. 1A Loupe images of two sections contain a solid lesion (atypical carcinoid: green line) and a cystic lesion (papillary adenocarcinoma: red line), which coexisted in proximity. The atypical carcinoid infiltrated into the papillary adenocarcinoma. B The atypical carcinoid, having finely granular nuclear chromatin, proliferated with an organoid pattern. C The wall of the cystic lesion was papillary adenocarcinoma. D, E The atypical carcinoid spread through veins and lymphatic vessels, and nests of carcinoid tumor (arrowhead) were observed in the adenocarcinoma component. There was a clear demarcation between the two tumor parts, without any histological transitions or intermingling between the two types of tumor cells. [b–e: bar = 100 μm]
Fig. 3Examples of immunohistochemistry of napsin A, surfactant protein A (SP-A), synaptophysin, chromogranin A, and insulinoma-associated protein 1 (INSM1). Adenocarcinoma components in case 1 and 2 were positive for napsin A and SP-A, and negative for synaptophysin, chromogranin A, and INSM1. Carcinoid components in case 1 and 2 were positive for synaptophysin, chromogranin A, and INSM1, and negative for napsin A and SP-A. Bar = 50 μm
Results of immunohistochemistry
| Antibody | Case 1 Ad | Case 1 NE | Case 2 Ad | Case 2 NE |
|---|---|---|---|---|
| 34βE12 | + | – | + | – |
| CAM5.2 | + | + | + | + |
| TTF-1 (clone: SPT24) | + | + | + | + |
| TTF-1 (clone: 8G7G3/1) | + | – | + | – |
| CEA | + | – | + | – |
| Napsin A | + | – | + | – |
| SP-A | + | – | + | – |
| CD56 | – | + | – | + |
| NSE | – | + | – | + |
| chromogranin A | – | + | – | + |
| synaptophysin | – | + | – | + |
| INSM1 | – | + | – | + |
| p53 | – | – | – | – |
| Ki-67 LI | < 1% | 16.7% | 2% | 3.2% |
NOTE Ad adenocarcinoma component, NE neuroendocrine tumor component, LI labeling index
Fig. 2A A macroscopic image of the cut lung surface. A white mass with pleural indentation was observed on the cut surface of the lung. B A loupe image of the mass. A nodule of carcinoid (green line) was observed close to the adenocarcinoma (red line). C A middle-power view of the boundary area of carcinoid (arrowhead) and adenocarcinoma (red line). The two components were distinct. Mild inflammation and fibrosis were observed between the two components. D, E High-power views of the carcinoid (d) and adenocarcinoma (e). [c–e: bar = 200 μm]
Previous reports of patients with non-neuroendocrine tumor + typical or atypical carcinoid in the lung
| Histology | Age/Sex | Smoking | Location | Ki-67 LI in TC/AC | Ki-67 LI in Ad/Sq | Tumor size | Metastasis/Histology | Reccurence | Survival/death | Refference | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | TC + Ad | 60/M | + | L/Peripheral | NA | NA | 20 mm | Lymph node/Ad | – | Survival | Sen, et al. 1998 [ |
| 2 | TC + Sq | 71/F | + | L/Central | < 1% | < 50% | 50 mm | Lymph node/NA | NA | NA | Owens, et al. 2011 [ |
| 3 | TC + Ad | 67/F | + | R/Peripheral | NA | NA | 18 mm | – | – | Survival | Nagamatsu, et al. 2011 [ |
| 4 | TC + Ad | 74/F | + | L/Peripheral | NA | NA | 13 mm | – | NA | NA | Abbi, et al. 2014 [ |
| 5 | AC + Sq | 71/M | + | R/Peripheral | NA | NA | 70 mm | – | Metastases to brain and adrenal | Died of pneumonia, 21 months after the surgery | Okazaki, et al. 2015 [ |
| 6 | AC + Ad | 66/M | + | R/Peripheral | NA | NA | 17 mm | – | – | Survival | Olofson, et al. 2018 [ |
| 7 | AC + Ad | NA | NA | Peripheral | NA | NA | NA | NA | – | Survival | Ruffini, et al. 2002 [ |
| 8 | TC + Sq | NA | NA | Peripheral | NA | NA | NA | NA | – | Survival | Ruffini, et al. 2002 [ |
| 9 | Carcinoid, NOS + Ad | 53/M | NA | R | NA | NA | NA | NA | NA | NA | Li, et al. 2015 [ |
| 10: Case 1 | AC + Ad | 77/F | - | L/Peripheral | 16.7% | < 1% | 29 mm | – | – | Survival | Present case |
| 11: Case 2 | TC + Ad | 83/F | + | L/Peripheral | 2.0% | 3.2% | 25 mm | – | – | Survival | Present case |
NOTE: TC Typical carcinoid, AC Atypical carcinoid, Ad Adenocarcinoma, Sq Squamous cell carcinoma, NOS not otherwise specified,
M Male, F Female, L Left, R Right, NA Not available, Ki-67 LI Ki-67 labeling index